Aligos Will Present Hepatitis Research in Denver
The company will share data on antiviral candidates at The Liver Meeting this November.
Updated on Oct. 5, 2026 in Biotech
Aligos Therapeutics will present five research abstracts at The Liver Meeting 2026, scheduled for November 5 through November 9 in Denver, Colorado. These research-stage findings focus on treatments for chronic hepatitis B and the hepatitis delta virus.
Why it matters
The company’s data updates provide insight into the development trajectory of its oligonucleotide and small molecule programs for liver disease. These presentations offer a formal review of performance data before the broader scientific community.
The accepted abstracts cover five specific research assets, including the performance of pevifoscorvir sodium and the preclinical profile of ALG-170675. Data also addresses the inhibition of hepatitis delta virus replication by the candidate ALG-215007.
The players
Aligos Therapeutics
A South San Francisco-based biotech company focused on developing therapies for liver diseases and viral infections using oligonucleotides and small molecules.
American Association for the Study of Liver Disease
A medical professional organization that facilitates research exchange and clinical practice guidelines for hepatology.
The details
The research findings submitted to the American Association for the Study of Liver Disease detail the pharmacological impact of these assets. Specifically, abstracts 4139 and 4142 analyze the effects of pevifoscorvir sodium on chronic hepatitis B patients and HBsAg levels, which are antigens that indicate current infection. Abstract 4158 benchmarks this candidate against existing nucleos(t)ide analogs, a class of antiviral drugs that mimic the building blocks of viral DNA to halt replication.
Timeline
November 5-9, 2026: The Liver Meeting 2026 takes place.
November 7, 2026: Presentation of abstract 3224.
November 8, 2026: Presentation of abstracts 4139, 4142, 4158, and 4156.
The Tech Race
The Liver Meeting serves as the primary scientific venue for validating new antiviral therapeutic candidates against established industry standards. Aligos’s presence indicates a push to position its pipeline alongside existing nucleos(t)ide therapies.
These developments currently exist at the research and presentation stage and do not affect clinical availability or patient care. Readers should monitor the post-conference release of these findings to track the technical efficacy of these experimental treatments.
The takeaway
The upcoming presentations will reveal how these specific candidates perform in viral replication inhibition compared to current standards. Watch the November 8 release of data for the benchmark results between pevifoscorvir sodium and existing nucleos(t)ide analogs.
Further reading
For broader trends in antiviral drug development, visit Biotech.
More information
View full documentation and conference schedules via The Liver Meeting abstract repository.
